Research interests include Neuroblastoma Research and Treatments, Nanoparticle-Based Drug Delivery, Ovarian cancer diagnosis and treatment, and Cancer Treatment and Pharmacology.
Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial
The Lancet Oncology2020cited by 326position: middledoi